Synovia Pharma brings ERTU to reduce diabetes patients’ kidney failure

Synovia Pharma has introduced - ERTU (Ertugliflozin) - the latest SGLT2 inhibitor that offers robust HbA1c control with a significant impact on safety and tolerability for the diabetic patients.

Eminent physician Professor A K Azad Khan, National Professor and President of the Diabetes Association of Bangladesh graced the event of ERTU as the Chief Guest, said a press release.

Professor Md Faruque Pathan, Professor of Endocrinology, BIRDEM General Hospital chaired the program where Professor S M Ashrafuzzaman - Professor and President of Bangladesh Endocrine Society was present as the Special Guest.

In the scientific part of the programme, Prof Indrajit Prasad – Professor and Head of Endocrinology, Dhaka Medical College Hospital presented on ‘Diabetes Management Focusing on CVD Outcome’ and Prof. Shamim Ahmed – Professor, National Institute of Kidney Diseases & Urology (NIKDU) presented on ‘Diabetes Management Focusing on Renal Protection’.

Professor Md. Nazrul Islam – Professor and Chairman, Dept of Nephrology, BSMMU (Bangabandhu Sheikh Mujib Medical University Hospital), Professor Mir Jamal Uddin – Professor and Director of NICVD (National Institute of Cardiovascular Diseases), Professor Md. Hafizur Rahman – Professor, United Hospital, Professor Feroz Amin – Professor and Head of Endocrinology, BIRDEM (Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine, and Metabolic Disorders),  Dr. Shahjada Selim – Associate Professor, BSMMU and Faria Afsana – Associate Professor, BIRDEM presented their expert opinion as the Panel of Experts.